Anthracycline Dose, Myocardial Injury, and Change in Left Ventricular Function in the Cardiac CARE Trial.

ABSTRACT:

Background

Anthracycline-induced toxicity contributes to long-term cardiovascular morbidity in cancer survivors. Cardiac troponin is recommended for risk stratification and diagnosis, but the relationship between troponin concentrations-particularly those measured using high-sensitivity assays-and subsequent cardiac dysfunction remains unclear.

Objectives

The authors sought to examine associations between high-sensitivity cardiac troponin I (hs-cTnI), cumulative anthracycline dose, number of treatment cycles, and changes in left ventricular (LV) function.

Methods

The Cardiac CARE trial was a prospective, multicenter, randomized, open-label, blinded-endpoint study of cardioprotective therapy in patients with elevated baseline hs-cTnI undergoing high-dose anthracycline

SUBMITTER: Loganath K 

PROVIDER: S-EPMC12790034 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature